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Abstract
Dissolution testing has emerged as an essential quality-control tool to monitor batch-to-batch
consistency during drug development. The aim of this study was to assess the dissolution
performance of drug products containing ibuprofen as active pharmaceutical ingredient available
on the Palestinian market. Ibuprofen is one of the most widely used analgesic, antipyretic and antiinflammatory over the counter (OTC) medication. Dissolution tests were performed using
simulated intestinal fluid (pH 7.2) in accordance to the specifications in the United States
Pharmacopoeia (USP). In vitro dissolution profiles of nine immediate-release ibuprofen
formulations (A-I) were evaluated and compared. Percent of drug released was determined by
spectrophotometric method. Comparison of dissolution profiles was done using similarity (f2) and
difference (f1) factors. In the present work dissolution in basic media (7.2 phosphate buffer) was
tested using a rotating paddle apparatus. The results obtained showed that the average drug release
after 60 minutes of products A-I exceeded 90%. All of the tested products passed the dissolution
test and met specifications in the USP. The results were above the Q value = 80 + 5% which is
recommended in the USP. Similarity and difference factors -when applied for both dosage forms
tablets and liquid capsules - showed that there were no significant differences of all tested products
compared to branded version of ibuprofen except product A (local tablet dosage form) compared to
its counterpart brand. Pertaining pharmacoeconomic aspects, our data revealed that customer prices
of ibuprofen products varied widely.
Keywords :Dissolution, Quality control, Ibuprofen, Palestine
Introduction:
The quality assessment of pharmaceutical
products is a basic responsibility of Quality
control (QC) unit. QC is concerned with the
finished product and any signs of defects or
deviations from set of
standards in
pharmacopoeias (1, 2). Dissolution testing is
considered as a valuable QC tool to monitor
batch-to-batch consistency during drug
development. However; dissolution testing
can be used for optimization of formulations
and monitoring drug stability over time (3,
4). It is also useful in providing
pharmaceutical product quality information
following post-approval changes to the
product such as changes in formulation,
changes to the manufacturing process or the
site of manufacture, and in process scaleup(3, 5). Nowadays, the use of generic

medicines has increased and many countries
which have enforced rules to provide safe,
effective, and good quality medications for
their population (1, 6). Besides, dissolution
testing is also employed as an alternative tool
for the assessment of in vivo bioequivalence.
In vivo bioequivalence studies are conducted
in healthy volunteers. These studies are
costly, time consuming and involve
subjecting healthy volunteers to risks of side
effects. However, today regulatory agencies
like the United State Food and Drug
Administration (FDA) and the European
Medicines Agency (EMA) allow the
replacement
(waiver)
of
in
vivo
bioequivalence studies by in vitro dissolution
testing especially for highly soluble drug
substances (i.e., Class I and III).
Accordingly, the in vitro dissolution test is
used to predict the in vivo absorption of the
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drug product, by means of in vivo/in vitro
correlations (IVIVC)(7-10).
Ibuprofen (IBP) is a non-steroidal drug
derived from propionic acid and is widely
used as an anti-inflammatory analgesic, and
has been approved as a nonprescription drug
since 1983(11).It has a pKa value of 4.5 and
is poorly soluble in water (0.078 μg/mL)(1214). According to the Biopharmaceutical
Classification System (BCS), IBP had been
classified as a class II drug (low solubility
and high permeability); therefore, drug
dissolution may be a rate limiting step in the
drug absorption process (15). IBP is well
absorbed orally; peak serum concentrations
are attained in 1 to 2 hours after oral
administration. It is rapidly bio-transformed
with an elimination half-life of 1.8 to 2 hours.
The drug is almost entirely eliminated by
hepatic metabolism within 24 hours after the
last dose(16).
Many studies and reports were published
in the literature assessing and comparing the
in vitro QC tests and particularly dissolution
performance of pharmaceuticals in Palestine
and worldwide (1, 17-20). To the best of our

knowledge there were no previous studies
conducted in Palestine evaluating the in vitro
dissolution performance of solid dosage
forms containing IBP. Therefore, the main
objective of the current study was to assess
the dissolution performance of solid oral
dosage forms containing IBP as active
pharmaceutical ingredient (API) available on
the Palestinian market. In addition, the
current work aimed to compare the
dissolution profiles and the percentage of
released IBP over specified time points of
these products.
Methods and Materials
Chemicals:
Potassium dihydrogen phosphate, sodium
hydroxide, and IBP powder were obtained
from
An-Najah
National
university
laboratory central stores. The tablets and
liquid capsules were obtained from the local
commercial pharmacy as any patient can buy
them from any pharmacy. Tablets have
strength of 400 mg, while liquid capsules
strengths are 200 and 400 mg. Table 1
reports a list of all tested products.

Table(1): A list of the tested products available on the Palestinian market.
Product

Dosage form

Manufacture

Price*

Strength(mg)

Expiry date

A

Tablet

Local

1.43

400

2/17

B

Tablet

Israel

1.43

400

9/15

C

Tablet

Local

1.43

400

1/17

D

Tablet

Local

1.43

400

3/19

E

Tablet

Israel

0.71

400

12/17

F

Tablet

Imported***

**

200

1/16

G

Liquid capsule

Imported

5.57

400

1/16

H

Liquid capsule

Local

1.71

400

1/17

I

Liquid capsule

Imported***

4.57

200

11/15

* USD $ /10unit, ** data are not available, *** reference product (brand)

Methods
Spectrophotometeric analysis of IBP: All
UV spectrophotometric measurements were
performed using a UV-vis spectrophotometer
(Jenway7315,
Staffordshire,
UK).
Determination of the percentage of dissolved
IBP was achieved based on the Beer’s plot.

Calibration curves were constructed for
buffer medium in standard solutions. A stock
solution of IBP was prepared by mixing 25
mg of IBP powder with 0.5 – 1 mL acetone
and sufficient quantity of distilled water to
make the solution 250 mL. The working
standard solutions of serial concentrations
(i.e., 2, 5, 10, 15, 20 and 25 µg/mL) were
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made by diluting the stock solution of IBP
with phosphate buffer. Five calibration
curves were made using linear regression of
the absorbance at λmax = 221 nm versus the
nominal concentration.

descriptive test designed to measure critical
points of physical failure in the sample.
Meaningful test data can be used for new
product development, quality control and
production efficiency. Liquid capsules
contain drug materials curried by liquid
vehicle encapsulated with a gelatin shell. The
shell should disintegrate in the presence of
fluid so that the contents are released. The
contents of soft capsules are usually solution
or suspension of the active ingredients in
non-aqueous liquids. Once the shell ruptured,
drug release occur, in which , drug release
percentage jumps for zero or low drug
release to more than 60% drug release, giving
its peak. Dissolution of the capsule shell
normally starts at the ends of the capsule,
tiny holes may be formed which continually
grow, causing rupture of the gelatin capsule
(21, 22).

Dissolution testing
In general the United States Pharmacopoeia
(USP) 2014 procedures were employed for
dissolution testing of the various products
under simulated intestinal fluid (SIF) i.e.,
buffer pH 7.2. Adjustment of pH values were
made using (Jenway 3520) pH meter that was
previously calibrated appropriately. Using a
rotating paddle apparatus Dissolution tester
(Hsiang Tai Machinery Industry Co Ltd,
Taiwan).Type II dissolution apparatus was
employed and the paddles were rotated at 50
rotations per minute (rpm). Samples were
withdrawn, filtered using a 1.0 μm
polyethylene micro-membrane filter, diluted
as appropriate and measured at 221nm.
Sampling points were set at 5, 10, 15, 20, 30,
45
and
60
minutes.
Compendial
specifications in the USP sets the QC
acceptance criterion for dissolution testing
when tolerances release not less than 85% of
the labeled quantity of IBP in 60 minutes (Q
value = 80 + 5%) in all tested products.

Dissolution comparison
The difference factor (f1) is proportional to
the average difference between the two
profiles, whereas f2 (similarity factor) is
inversely proportional to the average squared
difference between the two profiles(23, 24).
According to FDA guide, generally f1 values
up to 15 (0-15) and f2 values greater than 50
(50-100) ensure sameness or equivalence of
the two curves(25). The values of f1 and f2
factors for test products versus reference
were calculated from the means of percent
dissolved at each time point according to
equations provided below(26).

Rupture time
Rupture time test for gelatin capsule
considered an easy way for qualifying and
quantifying the film strength of the gel
capsule. It gives indications on the
dissolution rate, it is also a straightforward


1
f 2  50  log 1 
n



( Rt  Tt ) 

t 1

n

 n

f 1    Rt  Tt 

  t 1
Where Rt and Tt are the percentages of
drug dissolved at each time point for the
reference and test products, respectively. An
f1 value greater than 15 indicates nonsimilarity, and an f2 value greater than 50
indicates significant similarity between the
two analyzed products
Results and Discussion
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The work described in this study focused
on the evaluation of the in vitro dissolution
profiles of nine local pharmaceuticals
containing IBP as API that are commercially
available on the Palestinian market. These
drug products are being formulated as tablets,
caplet, and liquid capsule. The dissolution
tests were performed using SIF (pH 7.2) in
accordance to specifications in the USP(2).
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There is an increasing need to evaluate the in
vitro performance of available products
containing IBP since it is among the most
commonly used medicines as a pain killer.
Dissolution testing of drug products plays an
important role as a QC tool to monitor batchto-batch consistency of drug release from a
dosage form and as an in vitro surrogate for
in vivo performance (27).

Linearity range
A linear relationship within the studied
concentration range (2-25 µg/mL) was
obtained. The linear regression equation of
the calibration curves made of standard
solutions in phosphate buffer solution is
presented in Figure 1.

1.4

absorbance

1.2

y = 0.0469x + 0.0224
R² = 0.9996

1
0.8
0.6
0.4
0.2
0
0

5

10

15

20

concentration (µg/mL)

25

30

Figure(1): Average calibration curve in phosphate buffer solution.

Dissolution testing
As expected, all tested products (A-I) met
pharmacopeial specifications in the first stage
(S1). The USP guidelines require in vitro
dissolution such that no unit is less than 85%
(Tolerances, Q value = 80% of the labeled
amount)dissolved within 60 min in 900 mL
phosphate buffer pH 7.2 under dissolution

conditions described previously. In addition,
all pharmaceutical products were subjected to
dissolution testing and the average drug
release percentage was determined after 5,
10, 15, 20, 30, 45 and 60 min. Figure 2
exemplified the % drug released –time
profile of a selected product.

Figure(2): A representative drug release profile of product F, the data are represented by average drug
release with SD.
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Our data showed that there was a clear
evident that product D and product E have
the shortest dissolution time with fastest
pattern of drug release, in which both
products released more than 80% of the
labeled drug substance within 5 min. and
attained 95% after 60 min. Whereas product
B, product C and product F required 15 min

to release about 85% of the drug of interest.
However, product A reached the 80% within
30 min from starting the dissolution testing.
Figure 3 and Figure 4 demonstrated the
average drug release-dissolution profiles for
tablet dosage forms (A-F) and liquid capsule
(G-I) products respectively.

Figure(3): Average drug release of tablet dosage form A - F.

Figure(4): Average drug release of liquid capsule dosage forms G, H and I.
The variations in the dissolution time for
the same drug material of release during the
first 60 min. time interval refers to many
factors. Some are within the dosage form

manufacturing:
milling,
mixing
and
compression force. These factors highly
affect the dissolution time and rate. Tablets
were prepared by direct compression method,

 ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــPalestinian Medical and Pharmaceutical Journal (PMPJ). 2018; 3(1): 31-38

36 “ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــAssessment of Dissolution Performance of ......”

in the first step, drug was milled in ball mill
for specific time, and then it is mixed with
other excipients using double cone blender
for certain time, the blended powder was
directly compressed using rotary tablet
punching Machine. Each step can affect the
dissolution rate and drug release. Milling
time has negative effect on dissolution, as the
milling time increased, dissolution time
decreased; due to higher dissolution, this may
be due to micronization of the drug particles
(3, 5, 28, 29). The dissolution properties of
tablet contains excipients, were found to be
affected by the type of excipient used. Some
will increase the dissolution rate and increase
the disintegration of the tablet, making the
dissolution time shorter. Lubrication mixing
time place an important role on rate process.
It can be concluded that the mixing time has
positive effect on dissolution time, as the pre
lubrication mixing time increase dissolution
time increase due to low dissolution. As we
increase the lubrication mixing time, more
uniformly binder mix in the powder, so
hardness of the tablet increase, so ultimately
release of the drug decrease(29, 30). Besides,
the compression force and speed are
considered influential factors. Increasing the
compression force will reduce the surface
area and the porosity, resulting in a highly
compact hard tablet that needs prolonged
time to disintegrate, dissolve and release the
drug particles leading to increase dissolution
time (31).
Rupture time
Based on release profile obtained for
Product G, H and I, the rapture times for
these products ranged between the 15 and 20
min after testing. These results are somehow
controversial to the expectations since; some
products with tablet forms were capable to
release their contents within less than 15 min.
However, rupturing of gelatin shell depends
on different factors such as agitation,
temperature and dissolution medium. These
factors have insignificant influence since

they were set constants. More importantly,
the shell composition is seen to play a key
point that affects the rupture time of gelatin
capsule. Different type of capsules shells are
presents,
(gelatin,
gelatin/polyethylene
glycol,
hydroxypropyl
methylcelulose
(HPMC)) (22). It was reported that the
maximum extent of drug dissolution was
significantly increased when HPMC were
used, the dissolution time is significantly
reduced, indicating a faster dissolution rate of
the drug. The addition of micro-fine cellulose
to the formulation as filler reduced the
dissolution time. Whereas the addition of
lactose monohydrate did not enhance drug
dissolution (32).Giving a delayed dissolution
time in liquid capsules can be explained by
that dissolution time of liquid capsules is a
multi-factorial process; so more than factor
can be involved
Data Analysis according to difference and
similarity factor
Tablet products that were subjected to
comparative analysis (A - F), the reference
product used to calculate f1 and f2 was
product F (Advil® as tablet form). Since
average drug release of more than 85%
attained within 15 min for products C, D and
E, only two products among the six products
(A, and B) necessitate comparison using f1
and f2 values. Hence, there is no valuable
need to calculate f1 and f2 values for product
C, D, and E. The analysis of product A to
Advil revealed that there is a significant
difference between dissolution profile of A
compared to F, the values of f1 and f2 were
24 and 31 respectively. However, looking
back to average percentage release of drug
results of product A and product F, it is
noticeable the reasonable difference between
these two profiles. Whereas, product B
showed f1 to be 9 and f2 to be 54 which
indicates that there is no difference between
product B and product F in its dissolution
profile. Table 2 summarizes the calculated
values of f1 and f2.

Table(2):Similarity and difference values of tested products compared to reference (brand)
products.
Product A
Product B
Product G
Product H
13
f1 value
24
9
10
53
f2 value
31
54
56
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For liquid capsule products, the tested
products were Product G, and product H,
while the reference was product I (Advil® in
the capsule form). The obtained results
showed that comparing product G with
Advil® provided a calculated f1 value of 10
and f2 value of 56. These findings reflect
similarity between the two profiles. Likely,
product H when compared to Advil®, was
found to be similar such that f1 was equal to
13 and f2 was equal to 53.
Limitations
The content of the active ingredient of
each tested product is not assessed against
the label claim. In addition, the dissolution
tests were performed on pH 7.2 only and
other media with different pH values were
not used for granting biowaiving purposes.
Besides, in vitro dissolution test might be an
indicator to investigate the interchangeability
of products. The study has not been assisted
by other methods like in vivo bioequivalence
study for better conclusion.
Conclusions
The obtained results showed that the
average drug release after 60 minutes of
tested products were above the Q value = 80
+ 5% which is reported in the USP and
therefore they passed the dissolution test and
met the specifications of the USP. On the
pharmacoeconomic side, it was observed that
there is wide range of prices set of IBP
products.
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